Harrow Health Inc. (HROW) is an emerging and dynamic company based in the United States that is heavily invested in the healthcare sector. It operates with a strong commitment towards innovating and driving growth in pharmaceuticals.
Founded in 2011 by Mark Baum as Imprimis Pharmaceuticals, the company started with the aim of improving the affordability and accessibility of the medications the world needs most. In 2018, the company rebranded to Harrow Health and continued to expand its product offerings while staying true to its mission.
Harrow Health Inc. operates with a vision of creating, developing, and rectifying inefficiencies in the healthcare marketplace. It seeks to identify promising pharmaceutical assets and compounds in the market, buying them and formulating strategies for their commercialization and ultimate success.
The company's unique business model is characterized by its vertical integration pattern. It operates on a diversified platform combining pharmaceutical compounding, drug innovation, and vision technologies. With its emphasis on the patient's needs and the delivery of quality healthcare, Harrow has been instrumental in developing more than 100 proprietary formulations for use in various medical disciplines including ophthalmology, urology, and otolaryngology.
Harrow's diverse portfolio not only supports various medical disciplines but also includes Harrow Health's wholly-owned subsidiary, Eton Pharmaceuticals which is focused on developing and commercializing innovative treatments for rare pediatric diseases. Another significant subsidiary is ImprimisRx, which operates a pharmaceutical compounding business from FDA-inspected facilities across the United States, providing accessible and high-quality medications to patients.
Harrow Health Inc. is characterized by its commitment to growth through innovation, its devotion to improving patient experiences and outcomes, and its dedication to addressing underlying market inefficiencies in the healthcare sector. Its strategy and the implementation of that strategy have placed them prominently on the healthcare map and back their potential as a company geared towards making a lasting impact.
As of the current time, its novel business approach, along with a strong pipeline of proprietary formulated medicines and specialized services tailored to individual patient needs, has underlined its strength as a contender in the healthcare industry. The future for Harrow Health Inc. is indeed promising as it constantly strives to bring transformative medications to market. Led by an experienced, focused, and committed leadership team, Harrow Health Inc. is certainly a company to watch in the ever-evolving pharmaceutical sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article highlights growth companies in the United States with high insider ownership, suggesting strong internal confidence and alignment with shareholder interests. It details three specific companies—Harrow (HROW), Intapp (INTA), and Frontier Group Holdings (ULCC)—showcasing their growth potential, recent strategic moves, and financial forecasts. The report also provides a list of the top 10 growth companies with significant insider ownership.
Harrow Inc (HROW) experienced a 3.2% stock drop, leading to its current price of $33.09. Despite this, GuruFocus's GF Value suggests the stock is undervalued at $43.74, indicating a potential investment opportunity. The company has a strong GF Score of 79/100, driven by high growth potential, but faces challenges in financial strength and significant insider selling.
Harrow, Inc. has appointed Andrew R. Boll, their current President and CFO, as the principal accounting officer, effective September 4, 2026. He succeeds Randall E. Pollard, who stepped down from the role. Boll will maintain both his existing positions and the new accounting officer duties without additional compensation, ensuring transparency in the company's financial leadership.
Harrow Inc (HROW) shares increased by 5.6% to $39.05, placing the stock between its 52-week range and indicating an 8.8% undervaluation according to GuruFocus' GF Value of $42.84. Despite a strong GF Score of 77/100, driven by high growth potential, the company faces concerns regarding its unprofitability, negative cash flow, weak financial strength, and significant net selling by insiders. Investors are advised to exercise caution and conduct thorough due diligence before investing in the company.
This article analyzes Harrow Health Inc. (HROW) using AI models to provide institutional trading strategies. Key findings indicate weak near and mid-term sentiment, with a neutral long-term outlook, and highlights an exceptional short setup. The analysis offers specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies across different time horizons.
Harrow Inc. announced positive results from a clinical study on its ocular anesthetic, IHEEZO, showing a significant 58% reduction in discomfort for patients undergoing intravitreal injections compared to proparacaine. This improvement in patient comfort could enhance compliance with eye treatments, according to William Blair analysts who maintain an Outperform rating on Harrow stock due to attractive long-term growth prospects.